secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001493152-23-027349
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma Q2 net loss $6.1M; FDA sets 700-patient bar for MAT2203 first-line
--------------------------------------------------------------------------------

- Q2 2023 revenue $0 (vs $1.1M in Q2 2022); net loss $6.1M ($0.03/sh) vs $5.9M.
- Cash and securities $22.5M at June 30, down from $28.8M; runway into Q3 2024.
- FDA requires ~700-patient non-inferiority trial (10% mortality margin) for first-line MAT2203 approval.
- Compassionate use: 15-year-old with leukemia and resistant mucor/aspergillus improved on MAT2203, no nephrotoxicity.
- Internal RNAi show in vitro activity; in vivo oral LNC data expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315223027349/0001493152-23-027349-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315223027349/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-027349

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer